Drug intelligence / Profile preview

rilertinib

Development stage: Phase 3
Lead developer: Nanjing Sanhome Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Rilertinib is an orally administered, pyrimidine-based irreversible epidermal growth factor receptor (EGFR) antagonist developed by Nanjing Sanhome Pharmaceutical. It targets specific EGFR mutations including T790M, exon 19 deletion, and exon 21 L858R mutation. Rilertinib is classified as a small molecule antineoplastic agent and has reached registration status for the treatment of non-small cell lung cancer (NSCLC), where it has demonstrated superior progression-free survival compared to gefitinib in patients with EGFR-mutated NSCLC[2][4][7]. Its mechanism involves irreversible inhibition of mutant EGFR signaling pathways that drive tumor growth.

Brand names: Sanrisso
Other names: rilertinib mesylateoritnib

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on rilertinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rilertinib.

Explore the full profile